Concepedia

Kelly McGlinchey

KM

Statistics

Publications

27

Citations

1.6K

H-Index

20

Active since

2004

Affiliations

Bristol-Myers Squibb (United States)(Current)

AstraZeneca (Netherlands)

Bristol-Myers Squibb (Germany)

AstraZeneca (Japan)

Altimmune (United States)

Kelly McGlinchey is an author at Bristol-Myers Squibb (United States) specializing in oncology, medicine, and immunotherapy.

ORCID

Publications per year

2004–2023

27

Publications

27

Targeting CD73 in the tumor microenvironment with MEDI9447

Carl Hay, Erin Sult, Qihui Huang et al. · OncoImmunology · 2016 · 288 citations · Full text

, , +17

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Feng Luo, Zheng Yang, Amy Camuso et al. · Clinical Cancer Research · 2006 · 149 citations

, , +13

Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies

Jonathan Rios‐Doria, Jay Harper, Raymond Rothstein et al. · Cancer Research · 2017 · 134 citations

, , +17

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC

Eric Tu, Kelly McGlinchey, Jixin Wang et al. · JCI Insight · 2022 · 109 citations · Full text

, , +17

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T <sub>H</sub> 1 response with a diverse TCR repertoire

Phillip A. Swanson, Marcelino Padilla, Wesley Hoyland et al. · Science Translational Medicine · 2021 · 108 citations · Full text

, , +17

1–5 of 27